Search Advanced

AIMS Medical Science

2024, Volume 11, Issue 1: 1-24. doi: 10.3934/medsci.2024001
Previous Article Next Article
Research article Topical Sections

The impact of cannabis legislation on benzodiazepine and opioid use and misuse

Running title: Cannabis laws impact on benzodiazepine and opioid use and misuse
  • 1.
    Department of Criminology and Criminal Justice, Green School of International and Public Affairs, Florida International University, Miami, FL, USA
  • 2.
    Modesto A. Maidique Campus, 11200 SW 8th Street, PCA-366A, Miami, FL 33199, USA
  • Received: 12 October 2023 Revised: 20 December 2023 Accepted: 15 January 2024 Published: 25 January 2024

  • Background

    Several have claimed that the overreliance on benzodiazepines for many approved and off-label uses poses substantial human and social consequences comparable to those observed with the opioid epidemic. In light of these problems, alternatives are required to properly manage patients. Numerous states now permit the use of medical cannabis to treat conditions, such as chronic pain, that were traditionally treated with benzodiazepines, opioids, or both. As patients and physicians seek alternative treatments, little is known about whether the presence of cannabis laws helps to alleviate the burdens caused by these more traditional medications owing to the displacement of benzodiazepines and/or opioids toward cannabis.

     Methods

    Using data from multiple years of the National Survey on Drug Use and Health (2017, 2018, 2019), the effect of Medical Marijuana Laws (MMLs) on benzodiazepine and/or opioid use and misuse is examined while controlling for a variety of demographic characteristics. Supplemental analysis also is performed including the 2020 and 2021 survey years.

     Results

    MMLs did not affect lone, legitimate benzodiazepine usage, but lower use of opioids and combinations of benzodiazepines and opioids was observed. MMLs appear to help attenuate benzodiazepine and/or opioid misuse to a substantial degree. Additional results suggest that the presence of an MML was related to annual, varying decreases in the use and misuse of benzodiazepines, opioids, and their combination across the years of data evaluated.

     Conclusions

    MMLs may serve to attenuate the consequences of benzodiazepine, opioid, and their combined use and/or misuse to varying degrees.

    Citation: Jamie L. Flexon, Lisa Stolzenberg, Stewart J. D'Alessio. The impact of cannabis legislation on benzodiazepine and opioid use and misuse[J]. AIMS Medical Science, 2024, 11(1): 1-24. doi: 10.3934/medsci.2024001

    Related Papers:

  • Background

    Several have claimed that the overreliance on benzodiazepines for many approved and off-label uses poses substantial human and social consequences comparable to those observed with the opioid epidemic. In light of these problems, alternatives are required to properly manage patients. Numerous states now permit the use of medical cannabis to treat conditions, such as chronic pain, that were traditionally treated with benzodiazepines, opioids, or both. As patients and physicians seek alternative treatments, little is known about whether the presence of cannabis laws helps to alleviate the burdens caused by these more traditional medications owing to the displacement of benzodiazepines and/or opioids toward cannabis.

     Methods

    Using data from multiple years of the National Survey on Drug Use and Health (2017, 2018, 2019), the effect of Medical Marijuana Laws (MMLs) on benzodiazepine and/or opioid use and misuse is examined while controlling for a variety of demographic characteristics. Supplemental analysis also is performed including the 2020 and 2021 survey years.

     Results

    MMLs did not affect lone, legitimate benzodiazepine usage, but lower use of opioids and combinations of benzodiazepines and opioids was observed. MMLs appear to help attenuate benzodiazepine and/or opioid misuse to a substantial degree. Additional results suggest that the presence of an MML was related to annual, varying decreases in the use and misuse of benzodiazepines, opioids, and their combination across the years of data evaluated.

     Conclusions

    MMLs may serve to attenuate the consequences of benzodiazepine, opioid, and their combined use and/or misuse to varying degrees.


    加载中


    Conflict of interest


    All authors declare no conflicts of interest in this paper.

    [1] Alamanda VK, Wally MK, Seymour RB, et al. (2020) Prevalence of opioid and benzodiazepine prescriptions for osteoarthritis. Arthritis Care Res 72: 1081-1086. https://doi.org/10.1002/acr.23933
    [2] Chen J, Are benzodiazepines the new opioids? The USA Yale Medicine, (2019). Available from: https://www.yalemedicine.org/news/benzodiazepine-epidemic
    [3] Bachhuber MA, Hennessy S, Cunningham CO, et al. (2016) Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am J Public Health 106: 686-688. https://doi.org/10.2105/AJPH.2016.303061
    [4] Lembke A, Papac J, Humphreys K (2018) Our other prescription drug problem. N Engl J Med 378: 693-695. https://doi.org/10.1056/NEJMp1715050
    [5] Limandri BJ (2018) Benzodiazepine use: the underbelly of the opioid epidemic. J Psychosoc Nurs Ment Health Serv 56: 11-15. https://doi.org/10.3928/02793695-20180521-03
    [6] Wright SL (2020) Limited utility for benzodiazepines in chronic pain management: A narrative review. Adv Ther 37: 2604-2619. https://doi.org/10.1007/s12325-020-01354-6
    [7] Dowell D, Haegerich TM, Chou R (2016) CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA 315: 1624-1645. https://doi:10.1001/jama.2016.1464
    [8] Kowalski-McGraw M, Green-McKenzie J, Pandalai SP, et al. (2017) Characterizing the interrelationships of prescription opioid and benzodiazepine drugs with worker health and workplace hazards. J Occup Environ Med 59: 1114-1126. https://doi.org/10.1097/JOM.0000000000001154
    [9] Maust DT, Kales HC, Wiechers IR, et al. (2016) No end in sight: benzodiazepine use in older adults in the United States. J Am Geriatr Soc 64: 2546-2553. https://doi.org/10.1111/jgs.14379
    [10] Abrams DI, Couey P, Shade SB, et al. (2011) Cannabinoid opioid interaction in chronic pain. Clin Pharmacol Ther 90: 844-851. https://doi.org/10.1038/clpt.2011.188
    [11] National Academies of Sciences, Engineering, and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington: The National Academies Press. https://doi.org/10.17226/24625
    [12] Hill KP (2015) Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. JAMA 313: 2474-2483. https://doi.org/10.1001/jama.2015.6199
    [13] Bachhuber MA, Saloner B, Cunningham CO, et al. (2015) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 174: 1668-1673. https://doi.org/10.1001/jamainternmed.2014.4005
    [14] Flexon JL, Stolzenberg L, D'Alessio SJ (2019) The effect of cannabis laws on opioid use. Int J Drug Policy 74: 152-159. https://doi.org/10.1016/j.drugpo.2019.09.013
    [15] Sarvet AL, Wall MM, Keyes KM, et al. (2018) Self-medication of mood and anxiety disorders with marijuana: higher in states with medical marijuana laws. Drug Alcohol Depend 186: 10-15. https://doi.org/10.1016/j.drugalcdep.2018.01.009
    [16] Whiting PF, Wolff RF, Deshpande S, et al. (2015) Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 313: 2456-2473. https://doi.org/10.1001/jama.2015.6358
    [17] Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health Public Use File, Codebook. The USA Substance Abuse and Mental Health Services Administration, (2022). Available from: https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health
    [18] Hemmelgarn B, Suissa S, Huang A, et al. (1997) Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 278: 27-31. https://doi.org/10.1001/jama.1997.03550010041037
    [19] National Institute on Drug Abuse, Drug overdose death rates. The USA National Institute on Drug Abuse, (2023). Available from: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
    [20] Simon LS (2011) Relieving pain in America: a blueprint for transforming prevention, care, education and research. J Pain Palliat Care 26: 197-198. https://doi.org/10.3109/15360288.2012.678473
    [21] Reuben DB, Alvanzo AA, Ashikaga T, et al. (2015) National Institutes of Health Pathways to prevention workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med 162: 295-300. https://doi.org/10.7326/M14-2775
    [22] Johannes CB, Le TK, Zhou X, et al. (2010) The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain 11: 1230-1239. https://doi.org/10.1016/j.jpain.2010.07.002
    [23] Volkow ND, McLellan AT (2016) Opioid abuse in chronic pain—misconceptions and mitigation strategies. N Engl J Med 374: 1253-1263. https://doi.org/10.1056/NEJMra1507771
    [24] Goodwin RD, Weinberger AH, Kim JH, et al. (2020) Trends in anxiety among adults in the United States, 2008–2018: rapid increases among young adults. J Psychiatr Res 130: 441-446. https://doi.org/10.1016/j.jpsychires.2020.08.014
    [25] Terlizzi EP, Villarroel MA, Symptoms of generalized anxiety disorder among adults: United States, 2019. The USA National Center for Health Statistics NCHS Data Brief, No. 378, 2020. Available from: https://www.cdc.gov/nchs/data/databriefs/db378-H.pdf
    [26] Nuckols TK, Anderson L, Popescu I, et al. (2014) Opioid prescribing: A systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 160: 38-47. https://doi.org/10.7326/0003-4819-160-1-201401070-00732
    [27] Jones CM, The latest prescription trends for controlled prescription drugs. The USA Food and Drug Administration, (2015). Available from: https://archives.nida.nih.gov/sites/default/files/cjonesnida-bhccprescriptiontrendsslides.pdf
    [28] Volkow ND, Baler RD, Compton WM, et al. (2014) Adverse health effects of marijuana use. N Engl J Med 370: 2219-2227. https://doi.org/10.1056/NEJMra1402309
    [29] Mallow PJ, Belk KW, Topmiller M, et al. (2018) Geographic variation in hospital costs, payments, and length of stay for opioid-related hospital visits in the USA. J Pain Res 11: 3079-3088. https://doi.org/10.2147/JPR.S184724
    [30] National Institute on Drug Abuse, Drug Overdose Death Rates. The USA National Institute on Drug Abuse, (2019). Available from: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates. (updated to 2023)
    [31] Chen Q, Larochelle MR, Weaver DT, et al. (2019) Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open 2: e187621. https://doi.org/10.1001/jamanetworkopen.2018.7621
    [32] Martell BA, O'Connor PG, Kerns RD, et al. (2007) Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 146: 116-127. https://doi.org/10.7326/0003-4819-146-2-200701160-00006
    [33] Jann M, Kennedy WK, Lopez G (2014) Benzodiazepines: A major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract 27: 5-16. https://doi.org/10.1177/0897190013515001
    [34] Carico R, Zhao X, Thorpe CT, et al. (2018) Receipt of overlapping opioid and benzodiazepine prescriptions among veterans dually enrolled in Medicare Part D and the Department of Veterans Affairs: A cross-sectional study. Ann Intern Med 169: 593-601. https://doi.org/10.7326/M18-0852
    [35] Gellad WF, Zhao X, Thorpe CT, et al. (2017) Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D. Subst Abus 38: 22-25. https://doi.org/10.1080/08897077.2016.1267071
    [36] Boehnke KF, Gangopadhyay S, Clauw DJ, et al. (2019) Qualifying conditions of medical cannabis license holders in the United States. Health Aff 38: 295-302. https://doi.org/10.1377/hlthaff.2018.05266
    [37] Boehnke KF, Litinas E, Clauw DJ (2016) Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 17: 739-744. https://doi.org/10.1016/j.jpain.2016.03.002
    [38] Corroon Jr JM, Mischley LK, Sexton M (2017) Cannabis as a substitute for prescription drugs—A cross-sectional study. J Pain Res 10: 989-998. https://doi.org/10.2147/JPR.S134330
    [39] Lucas P (2012) Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs 44: 125-133. https://doi.org/10.1080/02791072.2012.684624
    [40] Lucas P, Walsh Z (2017) Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy 42: 30-35. https://doi.org/10.1016/j.drugpo.2017.01.011
    [41] Piper BJ, DeKeuster RM, Beals ML, et al. (2017) Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol 31: 569-575. https://doi.org/10.1177/0269881117699616
    [42] Reiman A, Welty M, Solomon P (2017) Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res 2: 160-166. https://doi.org/10.1089/can.2017.0012
    [43] Socias ME, Wood E, Lake S, et al. (2018) High-intensity cannabis use is associated with retention in opioid agonist treatment: A longitudinal analysis. Addiction 113: 2250-2258. https://doi.org/10.1111/add.14398
    [44] Burns TL, Ineck JR (2006) Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 40: 251-260. https://doi.org/10.1345/aph.1G217
    [45] Lau N, Sales P, Averill S, et al. (2015) A safer alternative: cannabis substitution as harm reduction. Drug Alcohol Rev 34: 654-659. https://doi.org/10.1111/dar.12275
    [46] Center for Behavioral Health Statistics and Quality, Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health, (HHS Publication No. SMA 16-4984, NSDUH Series H-51). The USA Substance Abuse and Mental Health Services Administration, (2016). Available from: http://www.samhsa.gov/data/
    [47] Bruce D, Brady JP, Foster E, et al. (2018) Preferences for medical marijuana over prescription medications among persons living with chronic conditions: alternative, complementary, and tapering uses. J Altern Complement Med 24: 146-153. https://doi.org/10.1089/acm.2017.0184
    [48] Powell D, Pacula RL, Jacobson M (2018) Do medical marijuana laws reduce addictions and deaths related to pain killers?. J Health Econ 58: 29-42. https://doi.org/10.1016/j.jhealeco.2017.12.007
    [49] Wen H, Hockenberry JM, Cummings JR (2015) The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. J Health Econ 42: 64-80. https://doi.org/10.1016/j.jhealeco.2015.03.007
    [50] Bradford AC, Bradford WD (2016) Medical marijuana laws reduce prescription medication use in Medicare part D. Health Aff 35: 1230-1236. https://doi.org/10.1377/hlthaff.2015.1661
    [51] Bradford AC, Bradford WD (2017) Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Aff 36: 945-951. https://doi.org/10.1377/hlthaff.2016.1135
    [52] Wen H, Hockenberry JM (2018) Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees. JAMA Intern Med 178: 673-679. https://doi.org/10.1001/jamainternmed.2018.1007
    [53] Kroenke K, Cheville A (2017) Management of chronic pain in the aftermath of the opioid backlash. JAMA 317: 2365-2366. https://doi.org/10.1001/jama.2017.4884
    [54] National Center of State Legislatures, State Medical Cannabis Laws. The USA National Center of State Legislatures, (2023). Available from: https://www.ncsl.org/health/state-medical-cannabis-laws
    [55] IBM Corp (2021) IBM SPSS Statistics for Windows, Version 28.0.0. Armonk, NY: IBM Corp. Available from: https://www.ibm.com/docs/en/spss-statistics/28.0.0
    [56] Substance Abuse and Mental Health Services Administration, Results from 2013 national survey on drug use and health: Summary of national findings. The USA Substance Abuse and Mental Health Services Administration, (2014). Available from: https://www.samhsa.gov/data/report/results-2013-national-survey-drug-use-and-health-summary-national-findings
    [57] Khatapoush S, Hallfors D (2004) “Sending the wrong message”: Did medical marijuana legalization in California change attitudes about and use of marijuana?. J Drug Issues 34: 751-770. https://doi.org/10.1177/002204260403400402
    [58] Schuermeyera J, Salomonsen-Sautela S, Price RK, et al. (2014) Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–2011. Drug Alcohol Depend 140: 145-155. https://doi.org/10.1016/j.drugalcdep.2014.04.016
    [59] Wall MM, Poh E, Cerda M, et al. (2011) Adolescent marijuana use from 2002 to 2008: higher in states with medical marijuana laws, cause still unclear. Ann Epidemiol 21: 714-716. https://doi.org/10.1016/j.annepidem.2011.06.001
    [60] Stolzenberg L, D'Alessio SJ, Dariano D (2016) The effect of medical cannabis laws on juvenile cannabis use. Int J Drug Policy 27: 82-88. https://doi.org/10.1016/j.drugpo.2015.05.018
    [61] Kalant H (2015) Cannabis control policy: no rational basis yet for legalization. Clin Pharmacol Ther 97: 538-540. https://doi.org/10.1002/cpt.112
    [62] Rehm J, Fischer B (2015) Cannabis legalization with strict regulation, the overall superior policy option for public health. Clin Pharmacol Ther 97: 541-544. https://doi.org/10.1002/cpt.93
    [63] Timko C, Cucciare MA (2018) Commentary on Socias et al. (2018): Clinical research perspectives on cannabis use in opioid agonist treatment. Addiction 113: 2259-2260. https://doi.org/10.1111/add.14432
    [64] MacCallum CA, Russo EB (2018) Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 49: 12-19. https://doi.org/10.1016/j.ejim.2018.01.004
    [65] Häuser W, Finnerup NB, Moore RA (2018) Systematic reviews with meta-analysis on cannabis-based medicines for chronic pain: A methodological and political minefield. Pain 159: 1906-1907. https://doi.org/10.1097/j.pain.0000000000001295
    [66] Lachenmeier DW, Rehm J (2015) Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci Rep 5: 8126. https://doi.org/10.1038/srep08126
    [67] Nutt DJ, King LA, Phillips LD (2010) Drug harms in the UK: A multicriteria decision analysis. Lancet 376: 1558-1565. https://doi.org/10.1016/S0140-6736(10)61462-6
    [68] van Amsterdam J, Opperhuizen A, Koeter M, et al. (2010) Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res 16: 202-207. https://doi.org/10.1159/000317249
    [69] Lake S, Socías ME, Milloy MJ (2020) Evidence shows that cannabis has fewer relative harms than opioids. CMAJ 192: E166-E167. https://doi.org/10.1503/cmaj.74120
    [70] Gable RS (1993) Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. Am J Drug Alcohol Abuse 19: 263-281. https://doi.org/10.3109/00952999309001618
    [71] Gable RS (2004) Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 99: 686-696. https://doi.org/10.1111/j.1360-0443.2004.00744.x
    [72] Pacula RL, Boustead AE, Hunt P (2014) Words can be deceiving: A review of variation among legally effective medical marijuana laws in the United States. J Drug Policy Anal 7: 1-19. https://doi.org/10.1515/jdpa-2014-0001
    [73] Walker JM, Huang SM (2002) Cannabinoid analgesia. Pharmacol Ther 95: 127-135. https://doi.org/10.1016/S0163-7258(02)00252-8
  • Reader Comments
  • © 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
AIMS Medical Science
0.7

Metrics

Article views(557) PDF downloads(234) Cited by(0)

Preview PDF
Download XML
Export Citation
Article outline

Figures and Tables

Tables(5)

Other Articles By Authors

Related pages

Tools

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog